Physician profile
Bridget Kaufman
NPI 1003202748
$8,665.58
in general payments reported to CMS, 2019-2025
23 companies · $2,916 in 2025
The $2,916 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $52.80 · 2021: $476 · 2022: $1,261 · 2023: $1,384 · 2024: $2,131 · 2025: $2,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,288 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,287.83 |
| Education | $143.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,885.25 | 2019-2025 | |
| Janssen Biotech, INC. | $778.71 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $690.99 | 2020-2025 | Dupixent, Libtayo |
| Pfizer INC. | $675.22 | 2021-2025 | |
| Lilly USA, LLC | $646.45 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $636.54 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Genzyme Corporation | $577.71 | 2021-2025 | |
| Amgen INC. | $549.08 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $394.54 | 2021-2025 | Odomzo, Blu-U, Absorica Ld |
| Ucb, INC. | $259.77 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $257.84 | 2021-2025 | Jublia, Arazlo, Duobrii |
| Allergan, INC. | $227.28 | 2019-2022 | |
| Journey Medical Corporation | $209.31 | 2022-2025 | |
| Incyte Corporation | $166.51 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $152.59 | 2023-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $143.05 | 2022-2025 | |
| Leo Pharma INC. | $137.12 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $67.86 | 2023-2024 | Sotyktu |
| Epi Health, LLC | $54.94 | 2022 | |
| Revance Therapeutics, INC. | $53.02 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $50.47 | 2025 | |
| Botanix Sb INC | $35.36 | 2025 | Sofdra |
| Lnhc, INC | $15.97 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.